The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.
One of the biggest problem areas in the fight against AMR is the research and development of new antibiotics. The science is hard and there is a problem with the current system for allocating investments into the expensive R&D needed to tackle superbugs that are always evolving.
Antibiotics are not like other medicines, because companies are working to find new medicines that in some cases will sit on the shelf and only be used against specific bugs – which are constantly evolving.
It can take 10 – 12 years and over a billion pounds to develop a new medicine and requires deep expertise, and that means there’s a big question mark over how we fund the research into antibiotics over the long-term that may only be used rarely.
But the new plan from the Government is a big step forward and could have a big impact on the future of health and research by making it sustainable for companies to keep investing. With AMR one of the biggest global health threats we face, pharmaceutical companies are keen to start finding solutions to this issue as soon as possible.
Read more here.